Literature DB >> 1557374

Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys.

P Chattopadhyay1, J Starkey, W J Morrow, S Raychaudhuri.   

Abstract

The mouse monoclonal antibody MEM136 (mAb1) is directed against an epitope on human melanoma-associated proteoglycan antigen (MPG). This epitope is also present on various normal human and subhuman tissues. A monoclonal murine anti-idiotope (anti-Id) antibody (mAb2), designated I-Mel-2, was generated against MEM136 and used as a surrogate antigen for the MPG molecule. I-Mel-2 was tested in cynomolgus monkeys (Macaca fascicularis) for its ability to induce anti-MPG humoral responses. All monkeys immunized with Ab2 developed specific anti-anti-idiotype (Ab3) responses that were capable of inhibiting binding of Ab2 to Ab1. Furthermore, I-Mel-2 immune monkey serum contained anti-MPG antibodies (Ab1') that bound to MPG-positive but not to MPG-negative melanoma cell lines. Monkeys immunized with Colo38 melanoma cells (membrane-bound MPG antigen) did not contain anti-MPG antibodies that inhibited the binding of two distinct anti-MPG mAb 125I-labeled MEM136 or 125I-labeled 225.28 to Colo38 cells. The induction of anti-MPG responses in monkeys did not cause any apparent side effects in animals, despite the fact that the MPG antigen is expressed by many normal tissues. The affinity-purified, I-Mel-2 idiotype-specific, Ab3 immunoprecipitated MPG antigen from melanoma cells. Furthermore, the I-Mel-2-induced Ab3 inhibited melanoma cell invasion in an in vitro assay, implying that these antibodies have biological significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557374      PMCID: PMC48726          DOI: 10.1073/pnas.89.7.2684

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Revised immune network concepts.

Authors:  H Köhler; T Kieber-Emmons; S Srinivasan; S Kaveri; W J Morrow; S Müller; C Y Kang; S Raychaudhuri
Journal:  Clin Immunol Immunopathol       Date:  1989-07

2.  Idiotypic replica of an anti-human tumor-associated antigen monoclonal antibody. Analysis of monoclonal Ab1 and Ab3 fine specificity.

Authors:  G Viale; G Flamini; F Grassi; R Buffa; P G Natali; M Pelagi; F Leoni; S Ménard; A G Siccardi
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

3.  Comparison of tumor cell invasion assays: human amnion versus reconstituted basement membrane barriers.

Authors:  M J Hendrix; E A Seftor; R E Seftor; R L Misiorowski; P Z Saba; P Sundareshan; D R Welch
Journal:  Invasion Metastasis       Date:  1989

4.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies.

Authors:  M Kusama; T Kageshita; Z J Chen; S Ferrone
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

6.  Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen.

Authors:  M Bhattacharya-Chatterjee; S Mukerjee; W Biddle; K A Foon; H Köhler
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

7.  Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen.

Authors:  S Raychaudhuri; Y Saeki; H Fuji; H Kohler
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

8.  Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta).

Authors:  S Raychaudhuri; Y Saeki; J J Chen; H Iribe; H Fuji; H Kohler
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

9.  Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones.

Authors:  C A Bona; E Heber-Katz; W E Paul
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

10.  The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface.

Authors:  H J Garrigues; M W Lark; S Lara; I Hellström; K E Hellström; T N Wight
Journal:  J Cell Biol       Date:  1986-11       Impact factor: 10.539

View more
  5 in total

Review 1.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

2.  CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes.

Authors:  J R Knutson; J Iida; G B Fields; J B McCarthy
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

3.  Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo.

Authors:  S Raychaudhuri; M Tonks; F Carbone; T Ryskamp; W J Morrow; N Hanna
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 4.  Animal models of human-derived cancer vaccines.

Authors:  D Herlyn; R Somasundaram; W Li; L Jacob
Journal:  Cell Biophys       Date:  1995-08

Review 5.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.